Full Press Release Details
Announces Financial Results for Quarter Ended September 30, 2024
Net Revenue of $3.5 Million;
Operational Improvements Result In First Profitable Quarter
ORANGE, NJ, November 7, 2024 - Nephros, Inc. (Nasdaq: NEPH), a leading water technology company providing filtration solutions
to the medical and commercial markets, today announced financial results for the third quarter ended September 30, 2024.
| Net income of $0.2 million, compared to a net loss of $0.2 million | ||
| Adjusted EBITDA of $295,000, compared to $11,000 | ||
| Net revenue of $3.5 million, an 8% increase over Q2 2024; a decrease of 6% over Q3 prior year |
performance is relative to same period in the prior year unless otherwise noted.
am very excited to report our first profitable quarter, marking a major milestone in our pursuit of achieving operational excellence.
I am also pleased to report we had positive-adjusted EBITDA for both the third quarter and first nine months of 2024," stated Robert
Banks, President and Chief Executive Officer. "Although most of our sales regions showed solid growth and steady performance with
existing customers, our [South Central] region continued to miss expectations, which resulted in some reorganization. Additionally, a
handful of our larger accounts exhibited slower-than-usual ordering patterns, as demonstrated by a slight decrease in same-site sales.
We continue to push forward with actions designed to mitigate the reduction in programmatic reorders, as outlined during our previous
Banks continued, "While Nephros prepares to launch digital support for filter installation, we are ramping up our service capabilities
to foster installation commissions and complement filter sales. We believe these efforts will offset customer non-compliance with filter
changeout schedules."
Performance for the Quarter Ended September 30, 2024
revenue for the quarter ended September 30, 2024, was $3.5 million, compared to $3.7 million in the corresponding period in 2023, a decrease
of 6%. The third quarter of 2023 was one of our largest quarters by revenue ever, with several new accounts placing initial orders of
significant size. Although those 2023 customers have continued to order, their 2024 replacement orders have been smaller by comparison.
Another contributing factor to our decreased quarterly revenue was underperformance across our South Central region, despite an 8% increase
from our prior quarter.
of goods sold for the quarter ended September 30, 2024, was $1.4 million, compared with $1.5 million for the quarter ended September
30, 2023, a decrease of 12%. Gross margins for the quarter ended September 30, 2024, were 61% compared to 59% for the quarter ended September
30, 2023, reflecting improved terms with our largest supplier.
and development expenses for each of the quarters ended September 30, 2024, and September 30, 2023, were $0.2 million. Depreciation and
amortization expense for the quarter ended September 30, 2024, was approximately $34,000, compared with approximately $55,000 for the
corresponding period in 2023.
general and administrative expenses for the quarter ended September 30, 2024, was $1.7 million compared to $2.1 million during the same
period in 2023 due to a decline in stock compensation and bonus accruals.
income for the quarter ended September 30, 2024, was $0.2 million, compared to a net loss of $0.2 million during the same period in 2023.
The decrease in net loss was driven by decreased operating expenses reflecting a reduction in bonus accrual and stock compensation expense.
Additionally, we continue our intense focus on managing expenses and working toward improving efficiency with the aim of providing our
unique products and services in a more streamlined manner.
EBITDA for the quarter ended September 30, 2024, was $295,000, compared to $11,000 during the same period in 2023 reflecting primarily
our operating profit for the quarter.
of September 30, 2024, Nephros had cash and cash equivalents of $2.5 million, compared to $4.3
million as of December 31, 2023. The decline in cash from year-end 2023 was driven primarily by the operating loss for the first
half of 2024, as well as payment of annual employee bonuses and an investment in inventory in the first quarter of 2024.
EBITDA Definition and Reconciliation to GAAP Financial Measures
EBITDA is calculated by taking net loss calculated in accordance with generally accepted accounting principles ("GAAP") and
excluding all interest-related expenses and income, tax-related expenses and income, non-recurring expenses and income, and non-cash
items, including depreciation, amortization, non-cash inventory write-offs, and non-cash compensation. The following tables present a
reconciliation of Adjusted EBITDA to net loss, the most directly comparable GAAP financial measure, for the third quarter and year to
date of the 2024 and 2023 fiscal years:
| Three Months Ended September 30, | ||||||||
| Consolidated Results | 2024 | 2023 | ||||||
| (in $ thousands) | ||||||||
| Reconciliation of net income (loss): | ||||||||
| Net Income (loss) | 183 | (182 | ) | |||||
| Adjustments: | ||||||||
| Depreciation of property and equipment | 12 | 9 | ||||||
| Amortization of other assets | 21 | 46 | ||||||
| Interest income | (20 | ) | (11 | ) | ||||
| Non-cash stock-based compensation | 65 | 149 | ||||||
| Non-cash inventory write-offs | 34 | - | ||||||
| Adjusted EBITDA Income | 295 | 11 |
| Nine Months Ended September 30, | ||||||||
| Consolidated Results | 2024 | 2023 | ||||||
| (in $ thousands) | ||||||||
| Reconciliation of net loss: | ||||||||
| Net Income (loss) | (275 | ) | (921 | ) | ||||
| Adjustments: | ||||||||
| Depreciation of property and equipment | 34 | 29 | ||||||
| Amortization of other assets | 68 | 134 | ||||||
| Interest expense | 1 | 1 | ||||||
| Interest income | (66 | ) | (36 | ) | ||||
| Non-cash stock-based compensation | 91 | 662 | ||||||
| Non-cash inventory write-offs | 214 | 106 | ||||||
| Adjusted EBITDA Income (loss) | 67 | (25 | ) |
Nephros believes that Adjusted EBITDA provides useful information to management and investors regarding certain financial and business
trends relating to Nephros' financial condition and results of operations. Management does not consider Adjusted EBITDA in isolation
or as an alternative to financial measures determined in accordance with GAAP. The principal limitation of Adjusted EBITDA is that it
excludes significant expenses and income that are required by GAAP to be recognized in Nephros' financial statements. In addition,
Adjusted EBITDA is subject to inherent limitations as it reflects the exercise of judgments by management about which expenses and income
are excluded or included in determining Adjusted EBITDA. To compensate for these limitations, management presents Adjusted EBITDA in
connection with net income loss, the most directly comparable GAAP financial measure. Nephros urges investors to review the reconciliation
of Adjusted EBITDA to net income loss and not to rely on any single financial measure to evaluate the business.
Call Today at 4:30pm ET
will host a conference call today at 4:30pm ET, during which management will discuss Nephros' financial results and provide a general
may dial into the call as follows:
Domestic access: 1 (844) 808-7106
International access: 1 (412) 317-5285
joining, please ask to be added into the Nephros conference call.
audio archive of the call will be available shortly after the call on the Nephros Investor Relations page.
a replay of the call may be accessed until November 14, 2024 at 1 (877) 344-7529 or 1 (412) 317-0088 for international callers and
entering replay access code: 5018166.
is committed to improving the human relationship with water through leading, accessible technology. We provide innovative water filtration
products and services, along with water-quality education, as part of an integrated approach to water safety. Nephros goods serve the
needs of customers within medical and commercial markets, offering both proactive and emergency solutions for water management.
more information about Nephros, please visit nephros.com.
release contains forward-looking statements that are subject to various risks and uncertainties. Such statements include statements regarding
Nephros' expected future revenue, gross margins, cash flows and expectations on maintaining positive cash flow and profitability,
and other future financial performance, the expected timing of the launch of new products and services, expected improvements in efficiency
in the delivery of our products and services, and other statements that are not historical facts, including statements that may be accompanied
by the words "intends," "may," "will," "plans," "expects," "anticipates,"
"projects," "predicts," "estimates," "aims," "believes," "hopes,"
"potential" or similar words. Actual results could differ materially from those described in these forward-looking statements
due to certain factors, including inflationary factors and general economic conditions, changes in business and competitive conditions,
fluctuations in customer order volumes, unpredictability with respect to revenue derived from emergency response orders, the availability
of capital when needed, dependence on third-party manufacturers and researchers, and regulatory reforms. These and other risks and uncertainties
are detailed in Nephros' reports filed with the U.S. Securities and Exchange Commission, including its Annual Report on Form 10-K
for the year ended December 31, 2023, which it may update in Part II, Item 1A - Risk Factors in its Quarterly Reports on Form 10-Q
that it has filed or will file hereafter. Nephros does not undertake any responsibility to update the forward-looking statements in this
| Kirin Smith, President | Robert Banks, CEO |
| PCG Advisory, Inc. | Nephros, Inc. |
| (646) 823-8656 | (201)343-5202x121 |
| ksmith@pcgadvisory.com | robert.banks@nephros.com |
NEPHROS, INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(In thousands, except share and per share amounts)
| Three Months Ended September 30, | Nine Months Ended September 30, | |||||||||||||||
| 2024 | 2023 | 2024 | 2023 | |||||||||||||
| Net revenue: | ||||||||||||||||
| Product revenues | $ | 3,472 | $ | 3,713 | $ | 10,186 | $ | 10,912 | ||||||||
| Royalty and other revenues | 46 | 29 | 106 | 72 | ||||||||||||
| Total net revenues | 3,518 | 3,742 | 10,292 | 10,984 | ||||||||||||
| Cost of goods sold | 1,369 | 1,548 | 4,044 | 4,600 | ||||||||||||
| Gross margin | 2,149 | 2,194 | 6,248 | 6,384 | ||||||||||||
| Operating expenses: | ||||||||||||||||
| Selling, general and administrative | 1,721 | 2,137 | 5,804 | 6,500 | ||||||||||||
| Research and development | 188 | 205 | 654 | 665 | ||||||||||||
| Depreciation and amortization | 34 | 55 | 101 | 163 | ||||||||||||
| Total operating expenses | 1,943 | 2,397 | 6,559 | 7,328 | ||||||||||||
| Operating income (loss) | 206 | (203 | ) | (311 | ) | (944 | ) | |||||||||
| Other (expense) income: | ||||||||||||||||
| Interest expense | - | - | (1 | ) | (1 | ) | ||||||||||
| Interest income | 20 | 11 | 66 | 36 | ||||||||||||
| Other income (expense), net | (43 | ) | 10 | (29 | ) | (12 | ) | |||||||||
| Total other expense: | (23 | ) | 21 | 36 | 23 | |||||||||||
| Net income (loss) | $ | 183 | $ | (182 | ) | $ | (275 | ) | $ | (921 | ) | |||||
| Net income (loss) per common share, basic | $ | 0.02 | $ | (0.02 | ) | $ | (0.03 | ) | $ | (0.09 | ) | |||||
| Net income (loss) per common share, diluted | $ | 0.02 | $ | (0.02 | ) | $ | (0.03 | ) | $ | (0.09 | ) | |||||
| Weighted average common shares outstanding, basic | 10,544,139 | 10,460,866 | 10,518,742 | 10,352,108 | ||||||||||||
| Weighted average common shares outstanding, diluted | 10,580,906 | 10,460,866 | 10,518,742 | 10,352,108 |
NEPHROS, INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED BALANCE SHEETS
(In thousands, except share and per share amounts)
| ASSETS | September 30, 2024 | December 31, 2023 | ||||||
| Current assets: | ||||||||
| Cash and cash equivalents | $ | 2,457 | $ | 4,307 | ||||
| Accounts receivable, net | 1,691 | 1,496 | ||||||
| Inventory | 3,099 | 2,470 | ||||||
| Prepaid expenses and other current assets | 109 | 132 | ||||||
| Total current assets | 7,356 | 8,405 | ||||||
| Property and equipment, net | 173 | 152 | ||||||
| Lease right-use-of assets | 1,461 | 1,807 | ||||||
| Intangible assets, net | 357 | 381 | ||||||
| Goodwill | 759 | 759 | ||||||
| License and supply agreement, net | 230 | 271 | ||||||
| Other assets | 50 | 86 | ||||||
| TOTAL ASSETS | $ | 10,386 | $ | 11,861 | ||||
| LIABILITIES AND STOCKHOLDERS' EQUITY | ||||||||
| Current liabilities: | ||||||||
| Accounts payable | 398 | 873 | ||||||
| Accrued expenses | 322 | 794 | ||||||
| Current portion of lease liabilities | 338 | 446 | ||||||
| Total current liabilities | 1,058 | 2,113 | ||||||
| Lease liabilities, net of current portion | 1,154 | 1,390 | ||||||
| TOTAL LIABILITIES | 2,212 | 3,503 | ||||||
| COMMITMENTS AND CONTINGENCIES | ||||||||
| STOCKHOLDERS' EQUITY: | ||||||||
| Preferred stock, $.001 par value; 5,000,000 shares authorized at September 30, 2024 and December 31, 2023; no shares issued and outstanding September 30, 2024 and December 31, 2023. | - | - | ||||||
| Common stock, $.001 par value; 40,000,000 shares authorized at September 30, 2024 and December 31, 2023; 10,544,139 and 10,543,675 shares issued and outstanding at September 30, 2024 and December 31, 2023, respectively. | 11 | 10 | ||||||
| Additional paid-in capital | 152,844 | 152,754 | ||||||
| Accumulated deficit | (144,681 | ) | (144,406 | ) | ||||
| TOTAL STOCKHOLDERS' EQUITY | 8,174 | 8,358 | ||||||
| TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY | $ | 10,386 | $ | 11,861 |